CCR2 Inhibitor CCX140 Not Moving Forward in Focal Segmental Glomerulosclerosis
CCX140, an orally-administered selective inhibitor, did not demonstrate a meaningful reduction in proteinuria in patients with primary focal segmental glomerulosclerosis (FSGS), according to top-line results from a phase 2 dose-ranging trial announced in a press release.
The LUMINA-1 trial tested CCX140 in 46 patients. After 12 weeks of blinded treatment, the CCR2 inhibitor did not show a meaningful reduction compared to the control group.
“With the CCR2 inhibitor CCX140 we desired to help people with FSGS,” said Thomas J. Schall, PhD, President and Chief Executive Officer of ChemoCentryx, in a press release. “Regrettably the data observed in the dose-ranging Phase II LUMINA-1 trial of CCX140 do not provide a productive way forward in this patient population.
Stefan Schulze, Chief Executive Officer Vifor Pharma Group said, “Unfortunately, the results of the Phase II LUMINA-1 trial are not what we have hoped for in the interests of patients suffering from this debilitating disease. These kind of setbacks are part of clinical development activities and do not affect our confidence in our strategy and ability to deliver strong growth from new and existing products in the future. Our overall partnership and collaboration with ChemoCentryx has been highly successful and is unaffected by this development.”
Primary focal segmental glomerulosclerosis is a rare kidney disorder characterized by progressive kidney damage.
Read the full press release here.